Biogen Gets EU Nod for First Postpartum Depression Drug

Biogen's Zurzuvae (zuranolone) has received European Commission approval for postpartum depression (PPD), making it the first and only oral treatment specifically indicated for PPD in the EU, following its FDA approval in August 2023. This approval addresses a significant unmet medical need in Europe and follows strong initial U.S. commercial performance, with Q2 2025 sales reaching $46.4 million, a 68% sequential increase that exceeded internal expectations, positioning Zurzuvae as a key growth driver for Biogen.

Analysis

Biogen has achieved a significant regulatory milestone with the European Commission's approval of Zurzuvae for postpartum depression (PPD), establishing it as the first and only approved treatment for this indication in the European Union. This approval is underpinned by strong Phase III data from the SKYLARK study, which demonstrated rapid and sustained symptom relief. The market opportunity is substantial, as Biogen estimates PPD symptoms affect 20% of recent mothers in the region. This European expansion builds upon a highly successful U.S. launch, where second-quarter 2025 sales reached $46.4 million, a 68% sequential increase that surpassed internal company projections. Zurzuvae is a key component of Biogen's four-product strategy aimed at reviving long-term growth, which is critical given the stock's 5% year-to-date decline against a 3% industry gain. Under the commercialization agreement, Biogen will record ex-U.S. sales and pay royalties to partner Supernus Pharmaceuticals, adding a potentially material new revenue stream.

Key Decisions for Investors

• Investors should evaluate the European market launch of Zurzuvae as a significant growth catalyst for Biogen, given its first-in-class status and the strong U.S. commercial uptake, which saw sales grow 68% sequentially to $46.4 million.
• The divergence between Biogen's fundamental progress with its new product pipeline and its 5% year-to-date stock decline suggests the market may be underappreciating the long-term revenue potential, warranting a re-evaluation of the stock's current valuation.
• Monitor upcoming quarterly reports for sustained momentum in Zurzuvae's U.S. sales and initial traction in the EU, as continued outperformance against expectations will be critical to reversing the stock's recent underperformance.